LEXINGTON, Mass., Jan. 4, 2018 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, today announced
that Dr. John Castle, Head of
Translational Medicine and Bioinformatics, will participate
in a panel entitled "IO on the Move: New Targets, New Trends,
New Combinations" on Wednesday, January
10,, 2018 at 9:00-10:00 am
P.T. at the 10th Annual Biotech Showcase™ at the
Hilton San Francisco Union Square.
Dr. John Castle is a pioneer in
translational bioinformatics and genomics and leader in the
identification of immune-inducing antigens for cancer therapy. At
Agenus, Dr. Castle will drive the application of mutational and
biochemical based neoantigens for the development and evaluation of
effective cancer treatments.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com; information
that may be important to investors will be routinely posted on our
website.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Dr. Castle's
participation in an upcoming panel and his anticipated
contributions to Agenus. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by
law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-dr-john-castle-joins-thought-leadership-panel-on-i-o-combinations-at-10th-annual-biotech-showcase-2018-300577565.html
SOURCE Agenus Inc.